How much has Lipitor lost (or gained) market share after generic entry?
I can’t answer this as stated because the provided information doesn’t include any data on Lipitor’s market share over the past year, nor any figures showing changes tied specifically to generic competition.
What counts as “past year” and what metric should be used?
“Market share” can mean different things, and the result can change depending on the measure and geography, for example:
- Retail vs. total prescriptions (including mail order)
- U.S. vs. global markets
- New prescriptions vs. total patient spend
- Dollar share vs. unit share
Without a source specifying which of these is being used, there’s no reliable way to quantify the effect of generics in the past 12 months.
What data would let us measure the impact of generic competition?
To determine how generic competition affected Lipitor’s market share over the past year, you would typically need at least one of the following time-series datasets:
- Monthly or quarterly prescription market share for atorvastatin products (brand vs. each generic)
- Monthly or quarterly sales share (units or dollars) for Lipitor vs. generics
- Claims data showing utilization shifts away from brand after generic penetration
If you share a source, I can compute the change
If you paste or link the market share figures you have for Lipitor (and the time period covered), I can calculate:
- The absolute change in market share over the past year
- The percent change
- Whether the shift lines up with the timing/extent of generic uptake
If you tell me the country (e.g., U.S.) and whether you mean unit share or dollar share, I can also align the calculation to that exact definition.
Sources
No sources were provided in your prompt, so I cited none.